|Other Names||Prostacyclin synthase, Prostaglandin I2 synthase, PTGIS, CYP8, CYP8A1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7997a was selected from the N-term region of human CYP8A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).|
|Cellular Location||Endoplasmic reticulum membrane; Single-pass membrane protein|
|Tissue Location||Widely expressed; particularly abundant in ovary, heart, skeletal muscle, lung and prostate|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP8A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. However, this protein is considered a member of the cytochrome P450 superfamily on the basis of sequence similarity rather than functional similarity. This endoplasmic reticulum membrane protein catalyzes the conversion of prostglandin H2 to prostacyclin (prostaglandin I2), a potent vasodilator and inhibitor of platelet aggregation. An imbalance of prostacyclin and its physiological antagonist thromboxane A2 contribute to the development of myocardial infarction, stroke, and atherosclerosis.
Nelson,D.R., Pharmacogenetics 14 (1), 1-18 (2004)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.